logoTry Persana

Guardian Bio - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Guardian Bio including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Guardian Bio company logo

Reinventing dendritic cell therapy for solid tumors

Guardian Bio focuses on creating personalized cell therapies based on dendritic cells to combat cancer.

HeadquartersNA
Team size1-10
Founded2022

What is Guardian Bio? - Company Overview & Details

Guardian Bio is Guardian Bio focuses on creating personalized cell therapies based on dendritic cells to combat cancer. Founded in 2022.

Who Founded Guardian Bio?

Guardian Bio was founded by Ananya Zutshi, Richard Barrett, PhD..

Who are the Key Executives at Guardian Bio? - Leadership Team

Guardian Bio is led by experienced executives in key positions:

Chief Executive Officer (CEO) of Guardian Bio

Ananya ZutshiCEO

Chief Technology Officer (CTO) of Guardian Bio

CTO

About Ananya Zutshi - CEO of Guardian Bio

Ananya Zutshi serves as the Chief Executive Officer of Guardian Bio, leading the company's strategic vision and operations. Connect with them on LinkedIn for professional insights.

Guardian Bio Company Details & Key Information

How many employees does Guardian Bio have?

Guardian Bio has 1-10 employees.

When was Guardian Bio founded?

Guardian Bio was founded in 2022.

Guardian Bio Official Website

How much funding has Guardian Bio raised?

Guardian Bio has raised $500,000 across 1 funding rounds. The most recent funding was completed on 2022-09-22.

Funding Overview

Guardian Bio raised $500,000 in a pre-seed funding round led by Y Combinator.

$500,000
Total Funding Raised
1
Funding Rounds
2022-09-22
Latest Round

Guardian Bio Funding History

Pre seed
2022-09-22
$500,000

Who are the key investors in Guardian Bio?

Guardian Bio is backed by 1 key investors including Y Combinator. These investors focus on Technology, Biotechnology sectors.

Guardian Bio Investor Overview

1
Key Investors
2
Focus Areas
0
Notable Investments

Complete List of Guardian Bio Investors

Y Combinator

A well-known startup accelerator.

Investment Focus
Technology
Biotechnology

What sectors do Guardian Bio investors focus on?

The investors backing Guardian Bio primarily focus on Technology, Biotechnology sectors.

Technology
Biotechnology

Featured Investor: Y Combinator

Y Combinator

A well-known startup accelerator.

Notable Investments:

What are Guardian Bio's future plans?

Guardian Bio Aim to move rapidly into clinical trials based on preclinical results.

Guardian Bio Strategic Outlook

Strategic Focus
Defined
2
Key Challenges
2
Growth Opportunities

What challenges does Guardian Bio face?

Guardian Bio has identified 2 key challenges that need to be addressed for continued growth and success.

Key Challenges for Guardian Bio

1

Navigating regulatory processes

2

Securing additional funding

What opportunities does Guardian Bio have?

Guardian Bio has identified 2 key opportunities for growth and market expansion.

Growth Opportunities for Guardian Bio

1

Expanding clinical trials

2

Building partnerships with research institutions

Guardian Bio Strategic Position Summary

Key Focus Areas

Guardian Bio is addressing 2 strategic challenges to strengthen its market position.

Growth Potential

The company has identified 2 key opportunities for expansion and growth.

What are the latest news about Guardian Bio?

Guardian Bio has 2 recent news updates covering key business developments and market activities.

Guardian Bio News Overview

2
Recent Articles
Active
Media Coverage
2024-09-18
Latest Update

What is Guardian Bio in the news for?

Guardian Bio is currently featured in news for Guardian Bio Featured at Harvard Business School and other significant business developments.

Recent News Articles About Guardian Bio

Article 1
2024-09-18

Guardian Bio Featured at Harvard Business School

Co-founders represented Guardian Bio at Harvard Business School as a case study.

Read News
Article 2
2024-07-20

Advancements in Dendritic Cell Therapy

Guardian Bio aims to enter clinical trials following promising preclinical results.

Nucleate
Read News

Guardian Bio FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Guardian Bio including information about founders, CEO, funding history, investors, headquarters location, and company details. 17 frequently asked questions covering key information about the company.

Guardian Bio Questions & Answers - Company Information

Q1

What is Guardian Bio?

Guardian Bio focuses on creating personalized cell therapies based on dendritic cells to combat cancer.

Q2

Who founded Guardian Bio?

Guardian Bio was founded by Ananya Zutshi, Richard Barrett, PhD..

Q3

Who is the CEO of Guardian Bio?

The CEO of Guardian Bio is Ananya Zutshi. You can find more information about them on their LinkedIn profile.

Q4

How much funding has Guardian Bio raised?

Guardian Bio has raised a total of $$500,000 across 1 funding rounds. The most recent funding was completed on 2022-09-22.

Q5

Who are the investors in Guardian Bio?

Guardian Bio's key investors include Y Combinator.

Q6

When was Guardian Bio founded?

Guardian Bio was founded in 2022.

Q7

How many employees does Guardian Bio have?

Guardian Bio has 1-10 employees.

Q8

What is Guardian Bio's official website?

You can visit Guardian Bio's official website at www.guardian-bio.com.

Q9

What was Guardian Bio's latest funding round?

Guardian Bio's latest funding round was a Pre seed round of $$500,000 completed on 2022-09-22.

Q10

Who is founder?

Ananya Zutshi

Q11

What does the company do?

Guardian Bio focuses on creating personalized cell therapies based on dendritic cells to combat cancer.

Q12

How much funding?

$500,000

Q13

Latest funding date?

2022-09-22

Q14

Who are the investors?

Y Combinator

Q15

What are the challenges?

Navigating regulatory processes Securing additional funding

Q16

What are the opportunities?

Expanding clinical trials Building partnerships with research institutions

Q17

Latest news?

Co-founders represented Guardian Bio at Harvard Business School as a case study. Guardian Bio aims to enter clinical trials following promising preclinical results.

More Information About Guardian Bio

For additional details about Guardian Bio, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.